Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. - Wikidata - awgldk - TriplyDB

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

http://www.wikidata.org/entity/Q50603777

about

Therapeutic interventions in severe asthma Allergic conjunctivitis in Asia.Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.Management of Grass Pollen Allergy with 5-Grass Pollen Tablet: Results of a 2-Year Real-Life Study.Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen.Efficacy of Sublingual Immunotherapy for House Dust Mite-Induced Allergic Rhinitis: A Meta-Analysis of Randomized Controlled Trials.Sublingual immunotherapy for allergic rhinitis: where are we now?Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma.Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis.Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper.Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma.A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma.Novel approaches and perspectives in allergen immunotherapy.Investigational new drugs for allergic rhinitis.Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis.Comparative analysis of the oral mucosae from rodents and non-rodents: Application to the nonclinical evaluation of sublingual immunotherapy products Immunotherapy of house dust mite allergy.Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.Perspectives in allergen immunotherapy: 2017 and beyond.Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.Extent of allergic inflammation depends on intermittent versus continuous sensitization to house dust mite.Sublingual immunotherapy tablets as a disease-modifying add-on treatment option to pharmacotherapy for allergic rhinitis and asthma.Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy.Clinical efficacy of sublingual immunotherapy is associated with restoration of steady-state serum lipocalin 2 after SLIT: a pilot study Sublingual allergen immunotherapy for respiratory allergy: a systematic review

P2860

Q28079238-B486AEC4-A7AC-4340-BDA5-E4F237A7022A Q30234510-F266359C-457C-447A-B48B-04AABB7B6CA1 Q33746919-21F3F30A-E652-45EA-9D18-85209009E838 Q33844444-34466DBE-247F-4191-AF6F-60F6C7A35944 Q36109358-6C641FFF-5A22-420E-AB7D-AD9C3A571FC8 Q36308157-55128F2B-53A8-406F-A214-54708FC078DF Q38617692-13DFE7A0-3B1B-43DD-9604-07F55F8C3302 Q38632661-E30926C5-34C8-4A65-8210-85E8C698CD1A Q38703027-0395A90D-EC0C-449F-9A99-F5C48AC7B645 Q38703818-62B65434-6D24-466B-94B0-010EA044B9E0 Q38765929-9EE13DC0-8CED-4C13-814A-3798B763C61C Q38870647-8EC9302D-1D38-4736-BE73-F756D4D83DFB Q38888019-8956F307-71D1-43DA-A841-6F9E51582EBD Q39037216-73707F83-481C-4F21-8EAC-2AF78385628C Q39103046-AE7ED897-CF9D-4641-9A3C-04769889B094 Q39111947-5AD0E3F8-C4DA-4C9D-889F-DE4327413597 Q39115606-0B612B0C-F3E4-4EA8-B46F-AEA133FC68AB Q39399204-D8ACE823-F206-47DB-90AA-88C39B95488D Q41495360-CB106626-462C-4D11-A2C2-0BCFDB5DCB00 Q43915564-37DE81F2-86CA-498C-BF92-9C3B377446B5 Q46337658-D3FD8DBD-25B1-4A84-86A3-D93F4CD81C71 Q47700986-2F8A3D27-6273-47CB-A951-232C9A9D2C0D Q47741028-854E903D-4BC0-4B6A-80A8-EBFCA71020A2 Q47761576-A154C9A9-0588-4855-9F89-F01616ED03F1 Q47918185-B66704EE-C91A-462C-A131-C0EFAB3A57BF Q47943200-321BB1B0-349A-4067-AA26-E0BA36C9A40E Q51557000-28C1A286-0303-4CF3-B32B-B960D33942A7 Q57489440-B34C90E8-8A47-4401-BD8E-23737A9AD312 Q58700135-34DD61BB-7F7B-4C62-B0C7-327A359FCF0C

P2860

Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.

http://www.wikidata.org/entity/Q50603777

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Onset and dose-related efficac ...... nvironmental exposure chamber.

@en

Onset and dose-related efficac ...... nvironmental exposure chamber.

@nl

type

label

Onset and dose-related efficac ...... nvironmental exposure chamber.

@en

Onset and dose-related efficac ...... nvironmental exposure chamber.

@nl

prefLabel

Onset and dose-related efficac ...... nvironmental exposure chamber.

@en

Onset and dose-related efficac ...... nvironmental exposure chamber.

@nl

P1433

Q50603777-6FDA716B-2AB2-4905-9D52-CBABF5F32A78

P1476

Q50603777-7CB153B6-BC0A-4102-BEF4-2BD8EFD64CDF

P2093

Q50603777-066D2C14-A183-4D77-ADDA-9D2F8FF1607B

Q50603777-094F095A-8ABE-4043-87E1-F8A2CD9A99C4

Q50603777-0C81B3FF-EAE2-427F-A1EA-529FD9D8DBBA

Q50603777-3A1B6F8E-8DEB-49CC-AA79-2B8CA6DC8753

Q50603777-4B243861-1BBF-4717-9246-DBCA0E3AB04D

Q50603777-538A064D-B8C6-4E7C-B446-7EFBE3F762BA

Q50603777-A0738042-0097-4ECA-815A-15BED7DE8516

Q50603777-B3AC980E-7B60-4B70-BE1C-882654AE2F0C

Q50603777-C07ED3E9-8884-4C4A-BAE4-20E69B26037B

Q50603777-C97C6ABE-DABA-408A-8749-32A5FA2BDC88

P304

Q50603777-42511ED7-85B9-4230-9660-18567C94B7FB

P31

Q50603777-FCEE1B62-D6F9-4E83-87BE-B88BC929CAD3

P356

Q50603777-2EB802F0-D9F2-45BF-B8E9-4AD86E6F4559

P407

Q50603777-056F3FFC-56DC-4685-995F-D06843B6309B

P433

Q50603777-53CF2F33-B2AE-4A61-9B29-3F237AC60EB6

P478

Q50603777-2ED9EA3F-83FB-45D7-B64C-92D1D976562F

P577

Q50603777-B6782F9F-C15E-42AE-BAC7-A1EAF0F59852

P5875

Q50603777-9E1EC7F6-9801-4248-9C57-2DFC48A42A4E

P698

Q50603777-327B0922-5F52-4458-B9BB-1FF52E22845C

P921

Q50603777-B7F206BC-12F4-4B37-949C-2016101D29C6

P356

J.JACI.2014.12.1911

P1433

The Journal of Allergy and Clinical Immunology

P1476

Onset and dose-related efficac ...... nvironmental exposure chamber.

@en

P2093

Amarjot Kaur

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

Friedrich Horak

http://www.w3.org/2001/XMLSchema#string

Harold S Nelson

http://www.w3.org/2001/XMLSchema#string

Hendrik Nolte

http://www.w3.org/2001/XMLSchema#string

Jennifer Maloney

http://www.w3.org/2001/XMLSchema#string

Patrick Lemell

http://www.w3.org/2001/XMLSchema#string

Petra Zieglmayer

http://www.w3.org/2001/XMLSchema#string

René Zieglmayer

http://www.w3.org/2001/XMLSchema#string

Susan Lu

http://www.w3.org/2001/XMLSchema#string

P304

1494-501.e6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2014.12.1911

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

135

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271648264

http://www.w3.org/2001/XMLSchema#string

P698

25636947

http://www.w3.org/2001/XMLSchema#string

P921